ClinicalTrials.gov posted results on 10 September 2026 for a completed Phase 2 study evaluating sonelokimab in adults with active psoriatic arthritis. The study enrolled 207 participants and included adalimumab as an active reference arm. At Week 12, the ACR50 response was 42.9% with adalimumab 40 mg Q2W, compared with 46.3% for sonelokimab 60 mg with induction.
Background
The trial evaluated subcutaneous sonelokimab against placebo in adults with active psoriatic arthritis. Adalimumab was included as an active reference treatment. The posted record listed sonelokimab, placebo, and adalimumab among the interventions, but did not provide additional drug-class or mechanism details.
Trial design
This completed Phase 2 study, identified as NCT05640245, enrolled 207 participants with psoriatic arthritis. The study included placebo, several sonelokimab regimens, and adalimumab 40 mg Q2W. The primary outcome was the percentage of participants achieving an ACR50 response at Week 12. The record also reported ACR20 responses at Weeks 2, 4, 8, and 12.
Key results
For ACR50 response at Week 12, the listed rates were 20.0% for placebo, 36.6% for sonelokimab 60 mg without induction, 46.3% for sonelokimab 60 mg with induction, 46.5% for sonelokimab 120 mg with induction, and 42.9% for adalimumab 40 mg Q2W.
The posted logistic-regression analyses for the ACR50 comparison reported odds ratios of 2.43 (95% CI, 0.882 to 6.695; p=0.086), 3.612 (95% CI, 1.32 to 9.884; p=0.012), and 3.992 (95% CI, 1.416 to 11.25; p=0.009). The supplied analysis entries did not specify which treatment comparisons corresponded to each estimate.
For the reported ACR20 measure, listed values included 12.5% for placebo, 24.4% for sonelokimab 60 mg without induction, 26.8% for sonelokimab 60 mg with induction, 25.6% for sonelokimab 120 mg with induction, and 19.0% for adalimumab 40 mg Q2W. Another listed ACR20 entry reported 30.0% for placebo and 48.8% for sonelokimab 60 mg without induction. The record also supplied ACR20 odds ratios of 6.067 (95% CI, 2.194 to 16.779; p=0.001), 6.531 (95% CI, 2.36 to 18.073; p=0.001), and 4.695 (95% CI, 1.807 to 12.2; p=0.002), without mapping each estimate to a specific comparison.
What this means
The posted results show similar Week 12 ACR50 response percentages for the adalimumab reference arm and the sonelokimab induction regimens. Because the supplied analysis entries do not identify the treatment comparison for each odds ratio, they do not support assigning a specific estimate to adalimumab or an individual sonelokimab dose. No adverse-event summary was provided in the data.
Source
Source: ClinicalTrials.gov, registry results for the completed Phase 2 study “Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis,” posted 10 September 2026. Available at clinicaltrials.gov/study/NCT05640245.